Hengrui Pharma Appoints New General Manager to Enhance Enterprise Transformation Momentum

On May 5, Hengrui Pharmaceutical announced that the company appointed Dai Hongbin as the general manager

According to the analysis of people familiar with the matter, Hengrui Medicine is currently in a critical period of transformation, and the adjustment of executive personnel for many times is obviously a necessary measure to stimulate the vitality of the organization, strengthen operation management, and increase the momentum of enterprise transformation

New general manager promoted from within

According to public information, Dai Hongbin's professional experience is quite stable.

Judging from his resume, Dai Hongbin has a combined educational background in law, economics and management.

In the context of industry shocks, Hengrui Pharmaceuticals, which is in a critical period of transformation, will inevitably experience pressure on its performance for a certain period of time.

Regarding this personnel appointment, Zhang Lianshan, Deputy General Manager of Hengrui Medicine and President of Global R&D, who has been in charge of the company's innovative research and development for many years, told reporters, "From a very early time, Chairman Sun Piaoyang has positioned Hengrui Medicine as a public enterprise, and the company's operations It relies on a perfect system and a team of professional managers

Adjustment of the senior management team to increase the momentum of transformation

Recently, many senior executives of Hengrui Medicine have resigned due to personal reasons, which has caused outside speculation

It is understood that Hengrui Medicine has always attached great importance to talent training.

It is understood that after the general manager took office, the division of labor of the main executive team of Hengrui Medicine has not changed much: Zhang Lianshan, deputy general manager of Hengrui Medicine and president of global R&D, is still in the field of innovative drug research and development.

The general manager with rich management experience is taking the new position, and the R&D veteran is in charge.

Anchoring innovation and internationalization, Hengrui accelerates transformation

Recently, in the context of industry changes and intensified competition, the adjustment of the pharmaceutical industry has entered a deep-water period

In terms of innovation, in recent years, Hengrui Medicine's R&D investment has maintained rapid growth year after year.

In terms of internationalization, Hengrui pharmaceutical products have entered more than 40 countries, and at the same time continue to accelerate the development of the global market

According to industry observations, the two strategies of innovation and internationalization have permeated Hengrui Pharmaceutical’s organizational system and become part of the corporate culture.